-
Singlomics Biopharmaceuticals to Present New Preclinical Data from IL1RAP mAb at the AACR 2024 Annual Meeting
Beijing, China, March 30, 2024-- Singlomics Biopharmaceuticals, a company committed to the discovery and development of antibody therapeutics for cancer and immune diseases using single-cell sequencing technologies, today announced a poster presentation of preclinical data from IL1RAP mAb at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10 in San Diego, California.
넶104 2024-03-27 -
Singlomics Completes CNY 300 Million Series B to Develop COVID-19 Antibodies and Other New Pipelines using High-throughput Single-cell Technology
Beijing, China, February 2, 2022 — Singlomics Biopharmaceuticals, an innovative biopharmaceutical company committed to the discovery and development of antibody drugs using single-cell sequencing technology platform, today announced the completion of close to CNY 300 million series B financing lead by LEGEND CAPITAL and MSA CAPITAL.
넶180 2022-08-28 -
CNBG Wuhan Institute of Biological Products Co., Ltd. and Singlomics Signed an Agreement on DXP-604 Project
At the end of December 2021, the Wuhan Institute of Biological Products, an entity of China National Biotech Group Co., Ltd. (CNBG), and Singlomics Biopharmaceuticals Co., Ltd. signed an agreement, allowing CNBG Wuhan to develop, manufacture and commercialize Singlomics’ DXP-604 product globally under its terms and conditions.
넶149 2022-08-29 -
Academician Xiaoliang Xie’s Team Has Discovered a Combination of Highly Potent and Fully Human Antibodies with Broad-spectrum Neutralizing Efficacy Against Concerning SARS-CoV-2 Variants
On August 25 2021, the research group of Dr. Xiaoliang Xie, the co-founder of Singlomics and professor of Beijing Advanced Innovation Center for Genomics (ICG), Peking University-Tsinghua University Joint Center for Life Sciences (CLS) and School of Life Sciences, Peking University, and the research group of Dr. Junyu Xiao, jointly published a research paper, "Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants" in Cell
넶108 2022-08-28 -
Singlomics Has Completed the First Round of Financing of Nearly RMB 100 Million and Uses the Single-cell Sequencing Technology to Drive New Drug Development
Singlomics Biopharmaceuticals Co., Ltd. (hereinafter referred to as Singlomics) recently announced that it has completed the first round of financing of nearly RMB 100 million. This round of financing was jointly led by GL Ventures and Huagai Healthcare, with BCSPD, BSTIG, Tianjin Huizhi and BOHE Angel Fund being the co-investors. The funds raised will be mainly used in advancing the company’s world-leading single-cell sequencing technology
넶136 2022-08-28 -
Singlomics Appoints Dr. Qian Shi as Chief Executive Officer (CEO)
On August 1, 2021, Singlomics Biopharmaceuticals Co., Ltd., a R&D company committed to using world-leading single-cell sequencing technology platforms to research and develop antibody drugs, and to promoting the discovery of innovative medicine for the treatment of infectious as well as autoimmune diseases and cancers, announced the appointment of Dr. Qian Shi as company CEO. Dr. Shi will be fully responsible for managing all departments of the company.
넶111 2022-08-28 -
BeiGene Announces an Exclusive License Agreement on Neutralizing Antibodies against SARS-CoV-2 Developed by Singlomics
On August 27, 2020, BeiGene (NASDAQ: BGNE; HKEX: 06160) and Singlomics Biopharmaceuticals Co., Ltd. announced they have entered into an exclusive license agreement. BeiGene will further develop, manufacture, and commercialize neutralizing antibodies against SARS-CoV-2 (including DXP-593 and DXP-604) under development by Singlomics globally, but outside Greater China. In preclinical studies
넶116 2022-08-28
